Vitiligo

Nanette Silverberg, MD, discusses new treatments for pediatric vitiligo, including JAK inhibitors and surgical advancements.

Nada Elbuluk, MD, MSc, emphasizes that medical treatments remain first-line for vitiligo, but stable cases may benefit from surgical options.

In his presentation at Winter Clinical Miami, Del Rosso covered a variety of topics including refractory pediatric vitiligo.

Emerging noninvasive imaging technologies, particularly optical coherence tomography, offer a revolutionary approach to monitoring vitiligo treatment responses.

Although more evidence is needed, CNNs could potentially be most effective in diagnosing patients with vitiligo.

Repibresib’s localized delivery minimizes systemic exposure while targeting inflammatory pathways, a novel approach for vitiligo management.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in vitiligo this year.

Larry Eichenfield, MD, discusses how fostering transparent communication with families affected by pediatric vitiligo involves addressing their concerns, setting realistic treatment expectations, providing emotional support, and empowering parents to be advocates for their children’s physical and emotional well-being.

Larry Eichenfield, MD, discusses how pediatric vitiligo can profoundly impact a child’s mental health, self-esteem, and social relationships, requiring a comprehensive care approach that includes psychological support, family counseling, and strategies to help children navigate peer interactions and build resilience.

Larry Eichenfield, MD, discusses how vitiligo manifests uniquely in children through its earlier onset patterns, rapid progression phases, specialized diagnostic challenges for developing skin, and modified treatment approaches that must carefully balance effectiveness with safety concerns for young patients.

Karan Lal, DO; Lisa Swanson, MD; James Song, MD; Andrew Alexis, MD, MPH; and Lawrence Eichenfield, MD, discussed the complexities of vitiligo care and the potential of innovative topical therapies.

Researchers emphasized the need for future studies to refine protocols and address economic barriers to combination therapy.

Karan Lal, DO, MS, FAAD, discusses how to balance safety and efficacy considerations while promoting treatment adherence in young vitiligo patients, focusing on the unique challenges and monitoring requirements for this vulnerable population.

Karan Lal, DO, MS, FAAD, discusses how to optimize vitiligo management in pediatric patients through personalized treatment selection and age-appropriate counseling strategies that address both the physical and psychosocial aspects of the condition.

Karan Lal, DO, MS, FAAD, discusses how treatment approaches for vitiligo differ between adult and pediatric populations, with experts examining distinct patterns of care, therapeutic considerations, and clinical pearls specific to each age group.

2024 saw significant progress in vitiligo treatments, including novel drugs, off-label uses, and updated pediatric guidelines for better outcomes.

Explore key insights and innovations in vitiligo from 2024, from treatment advances to patient-focused strategies.

LOV has unique clinical traits, epidemiology, and treatment responses compared to early-onset vitiligo, underscoring the need for a tailored management approach.

Regenerative methods such as cell therapy and platelet-rich plasma showed promising results in patient repigmentation.

Learn more about the in-depth topics covered in the November 2024 AD and Vitiligo supplement of Dermatology Times.

In a Dermatology Times Case-Based Peer Perspective event, Terry Faleye, MPAS, PA-C, reviewed 2 cases of patients with vitiligo to discuss innovative treatments and emotional challenges with disease management.

Researchers stated the dual-action therapy could offer a promising approach to treat progressive non-segmental vitiligo.

VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.

Learn more about the in-depth topics covered in the October 2024 vitiligo supplement of Dermatology Times.

In a Dermatology Times Case-Based Roundtable event, Pearl E. Grimes, MD, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.